Zenith Capital Corp. (ZHCLF)
USD 0.0
(-99.9%)
USD 0.0
(-99.9%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.94 Million USD | -20.52% |
| 2022 | 11.25 Million USD | 149946.67% |
| 2021 | 7499.00 USD | 10.9% |
| 2020 | 6762.00 USD | -29.4% |
| 2019 | 9578.00 USD | -15.34% |
| 2018 | 11.31 Thousand USD | -99.87% |
| 2017 | 8.5 Million USD | 22.94% |
| 2016 | 6.91 Million USD | -15.31% |
| 2015 | 8.16 Million USD | 3.84% |
| 2014 | 7.86 Million USD | -59.0% |
| 2013 | 19.18 Million USD | 80.56% |
| 2012 | 10.62 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.38 Million USD | 18.0% |
| 2023 Q4 | 1.17 Million USD | -39.02% |
| 2023 Q2 | 3.01 Million USD | -6.35% |
| 2023 Q1 | 3.21 Million USD | -58.52% |
| 2023 Q3 | 1.92 Million USD | -36.15% |
| 2022 Q3 | 1773.90 USD | -18.29% |
| 2022 Q1 | 1118.00 USD | -99.92% |
| 2022 FY | 12.8 Million USD | 170629.43% |
| 2022 Q2 | 2171.00 USD | 94.19% |
| 2022 Q4 | 7.74 Million USD | 436734.09% |
| 2021 Q4 | 1.45 Million USD | -22.8% |
| 2021 Q1 | 2.24 Million USD | 49.14% |
| 2021 Q2 | 1.99 Million USD | -10.97% |
| 2021 Q3 | 1.89 Million USD | -5.36% |
| 2021 FY | 7499.00 USD | 10.9% |
| 2020 Q2 | 1.78 Million USD | 3.6% |
| 2020 FY | 6762.00 USD | -29.4% |
| 2020 Q3 | 1.74 Million USD | -2.02% |
| 2020 Q4 | 1.5 Million USD | -14.01% |
| 2020 Q1 | 1.72 Million USD | -24.69% |
| 2019 Q1 | 1.7 Million USD | -59.15% |
| 2019 FY | 9578.00 USD | -15.34% |
| 2019 Q4 | 2.28 Million USD | -20.14% |
| 2019 Q3 | 2.86 Million USD | 5.21% |
| 2019 Q2 | 2.72 Million USD | 59.99% |
| 2018 Q4 | 4.16 Million USD | 61.29% |
| 2018 FY | 11.31 Thousand USD | -99.87% |
| 2018 Q3 | 2.58 Million USD | 5.39% |
| 2018 Q2 | 2.45 Million USD | 15.94% |
| 2018 Q1 | 2.11 Million USD | -23.79% |
| 2017 Q2 | 826 Thousand USD | -64.37% |
| 2017 Q3 | 2.58 Million USD | 213.32% |
| 2017 Q1 | 2.31 Million USD | -1.82% |
| 2017 FY | 8.5 Million USD | 22.94% |
| 2017 Q4 | 2.77 Million USD | 7.19% |
| 2016 FY | 6.91 Million USD | -15.31% |
| 2016 Q4 | 2.36 Million USD | 31.61% |
| 2016 Q3 | 1.79 Million USD | 5.9% |
| 2016 Q2 | 1.69 Million USD | 58.76% |
| 2016 Q1 | 1.06 Million USD | -46.33% |
| 2015 FY | 8.16 Million USD | 3.84% |
| 2015 Q1 | 2.04 Million USD | -16.13% |
| 2015 Q4 | 1.98 Million USD | 12.44% |
| 2015 Q3 | 1.76 Million USD | -25.27% |
| 2015 Q2 | 2.36 Million USD | 15.75% |
| 2014 Q4 | 2.43 Million USD | 894.69% |
| 2014 Q1 | 3.65 Million USD | -55.36% |
| 2014 FY | 7.86 Million USD | -59.0% |
| 2014 Q3 | 245 Thousand USD | -83.99% |
| 2014 Q2 | 1.53 Million USD | -58.12% |
| 2013 Q2 | 3.53 Million USD | 3.06% |
| 2013 Q3 | 4.02 Million USD | 13.73% |
| 2013 Q4 | 8.18 Million USD | 103.3% |
| 2013 Q1 | 3.43 Million USD | 5.92% |
| 2013 FY | 19.18 Million USD | 80.56% |
| 2012 FY | 10.62 Million USD | 0.0% |
| 2012 Q4 | 3.24 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -569.671% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -77.369% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 69.739% |
| Nascent Biotech, Inc. | 2.22 Million USD | -301.053% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1246.837% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 75.996% |
| Qrons Inc. | 643.67 Thousand USD | -1289.361% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2195.632% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 84.431% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2052.455% |
| Skye Bioscience, Inc. | 13.54 Million USD | 33.988% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 89.695% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -81.845% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3316.932% |
| SQZ Biotechnologies Company | 85.61 Million USD | 89.555% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -206.663% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -495.446% |
| Mesoblast Limited | 5.9 Million USD | -51.525% |
| Marizyme, Inc. | 19.23 Million USD | 53.518% |
| Genus plc | 147.7 Million USD | 93.945% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1.865% |
| Pharming Group N.V. | 225.49 Million USD | 96.034% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -336.52% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -566.619% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -7.243% |
| ContraFect Corporation | 56.88 Million USD | 84.28% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -102.85% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -504.767% |
| IMV Inc. | 37.7 Million USD | 76.284% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -220.497% |
| MultiCell Technologies, Inc. | 567.42 USD | -1575981.21% |
| ONE Bio Corp. | 6.44 Million USD | -38.783% |
| Accustem Sciences Inc. | 3.74 Million USD | -138.708% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 89.595% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1581.135% |
| Q BioMed Inc. | 3.43 Million USD | -160.226% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 63.815% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -240.359% |
| Biomind Labs Inc. | 994.18 Thousand USD | -799.533% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 90.997% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -408.218% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -33.12% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -379.679% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 35872.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 44.142% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -387.332% |
| GB Sciences, Inc. | 1.42 Million USD | -529.563% |
| Alpha Cognition Inc. | 9.7 Million USD | 7.857% |
| HST Global, Inc. | 140.9 Thousand USD | -6246.739% |
| CSL Limited | 3.44 Billion USD | 99.741% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -694.997% |
| Halberd Corporation | 74.84 Thousand USD | -11849.173% |
| Enzolytics Inc. | 2.17 Million USD | -310.322% |
| Agentix Corp. | 1.37 Million USD | -551.938% |
| Resverlogix Corp. | 12.71 Million USD | 29.649% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -144.966% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.417% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -756.609% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -271.861% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -466.244% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -162.645% |
| AVAX Technologies, Inc. | 7.31 Million USD | -22.335% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.916% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -51234.596% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -264.23% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5114.304% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -365.562% |
| Kadimastem Ltd | 2.41 Million USD | -271.062% |
| Helix BioMedix, Inc. | 1.97 Million USD | -353.491% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 17.705% |
| BioStem Technologies, Inc. | 22.97 Million USD | 61.075% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4827.68% |
| LadRx Corporation | 3.81 Million USD | -134.614% |
| Cell Source, Inc. | 4.32 Million USD | -106.758% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -868.371% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -868.371% |
| NovAccess Global Inc. | 2.46 Million USD | -262.54% |
| Affymax, Inc. | 39.38 Million USD | 77.294% |
| Itoco Inc. | 919.14 Thousand USD | -872.972% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -110.999% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -699.196% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1512.671% |
| CytoDyn Inc. | 18.05 Million USD | 50.476% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -35431.805% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3963.559% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -529.881% |
| SYBLEU INC | 160.87 Thousand USD | -5458.94% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -392.369% |
| International Stem Cell Corporation | 5.27 Million USD | -69.664% |
| Bioxytran, Inc. | 3.82 Million USD | -134.101% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -16888.336% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -43861.068% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 75.341% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -452.719% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1115.354% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -187.464% |
| Neutra Corp. | 243.82 Thousand USD | -3567.855% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 48.771% |
| PureTech Health plc | 144.59 Million USD | 93.815% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 56.354% |
| IXICO plc | 4.7 Million USD | -89.994% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1.66% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 92.405% |
| CSL Limited | 3.89 Billion USD | 99.77% |
| Cellectis S.A. | 97.32 Million USD | 90.811% |